Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction

Journal of Urology

Volumn 173, Issue 1, 2005, Pages 221-225

  Franco, Israel ^a   Horowitz, Mark ^b   Grady, Richard ^c   Adams, Richard C ^d   De Jong, Tom P V M ^e   Lindert, Kelly ^f   Albrecht, Detlef ^f  

^a Pediatric Urology Associates   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Center for Cancer and Blood Disorders   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ALZA CORPORATION   (United States)

Author keywords

Bladder, neurogenic; Cholinergic antagonists; Safety

Indexed keywords

OXYBUTYNIN;

ADOLESCENT; ANTICHOLINERGIC EFFECT; ARTICLE; BLADDER PRESSURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR DYSSYNERGIA; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTERMITTENT CATHETERIZATION; MALE; MULTICENTER STUDY; NEUROGENIC BLADDER; OPEN STUDY; OTITIS MEDIA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SYRUP; TABLET FORMULATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE CATHETER; URINE VOLUME; URODYNAMICS; VASCULAR DISEASE; VASODILATATION; XEROSTOMIA;

EID: 10344234759     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000147813.28822.d2     Document Type: Article

References (12)

1. Goessl, C., Knispel, H. H., Fiedler, U., Harle, B., Steffen-Wilke, K. and Miller, K.: Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology, 51: 94, 1998
2. Aslan, A. R. and Kogan, B. A.: Conservative management in neurogenic bladder dysfunction. Curr Opin Urol, 12: 473, 2002
3. Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U. et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn, 21: 167, 2002
4. Mulcahy, J. J., James, H. E. and McRoberts, J. W.: Oxybutynin chloride combined with intermittent clean catheterization in the treatment of myelomeningocele patients. J Urol, 118: 95, 1977
5. Youdim, K. and Kogan, B. A.: Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology, 59: 428, 2002
6. Madersbacher, H. G.: Neurogenic bladder dysfunction. Curr Opin Urol, 9: 303, 1999
7. Sathyan, G., Chancellor, M. B. and Gupta, S. K: Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol, 52: 409, 2001
8. Gupta, S. K. and Sathyan, G.: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol, 39: 289, 1999
9. Madersbacher, H.: Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol, 12: 469, 2002
10. van Gool, J. D., Dik, P. and de Jong, T. P.: Bladder-sphincter dysfunction in myelomeningocele. Eur J Pediatr, 160: 414, 2001
11. Dik, P., Tsachouridis, G. D., Klijn, A. J., Uiterwaal, C. S. P. M. and de Jong, T. P. V. M.: Detrusorectomy for neuropathic bladder in patients with spinal dysraphism. J Urol, 170:1351, 2003
12. Kaefer, M., Pabby, A., Kelly, M., Darbey, M. and Bauer, S. B.: Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomeningocele. J Urol, 162: 1068, 1999